drugset / Trial / NCT00832000

Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia

NCT00832000

Phase 2 Completed 59 enrolled Richard Barohn, MD
RandomizedCrossoverDouble-blindTreatment

Summary

Nondystrophic myotonias (NDM) are neuromuscular disorders caused by genetic abnormalities in certain muscle cell membrane proteins. The proteins affect muscle contraction. Individuals with NDM experience limited muscle relaxation, which then can cause pain, weakness, incoordination, and impaired physical activity and function. Because NDM is very rare, information on the best way to treat people with the disorders is lacking, and there are no FDA-approved therapies. The purpose of this study is to determine the effectiveness of the medication mexiletine in treating people with NDM.

Timeline

Start
2008-12
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mexiletine Small molecule 200 mg Oral